<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702115</url>
  </required_header>
  <id_info>
    <org_study_id>SB-318-1502</org_study_id>
    <nct_id>NCT02702115</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I</brief_title>
  <official_title>A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability of ascending doses of&#xD;
      SB-318. SB-318 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for&#xD;
      genome editing. It inserts a correct copy of the α-L-iduronidase (IDUA) gene into the Albumin&#xD;
      locus in hepatocytes with the goal of lifelong therapeutic production of the IDUA enzyme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to provide long term expression of IDUA and improve the&#xD;
      current clinical outcome of enzyme replacement therapy (ERT) or hematopoietic stem cell&#xD;
      transplantation (HSCT) therapy in subjects with attenuated MPS I, a recessive lysosomal&#xD;
      storage disorder that results from mutations in the gene encoding IDUA. SB-318 is a&#xD;
      therapeutic for ZFN-mediated genome editing which will be delivered by adeno-associated virus&#xD;
      (AAV)-derived vectors. SB-318 is intended to function by placement of the corrective copy of&#xD;
      the IDUA transgene into the genome of the subject's own hepatocytes, under the control of the&#xD;
      highly expressed endogenous albumin locus, and is expected to provide permanent,&#xD;
      liver-specific expression of iduronidase for the lifetime of an MPS I patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive SB-318 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-318 on IDUA activity</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Change from baseline clinical laboratory in measurement of IDUA activity measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-318 on urine glycosaminoglycans (GAG) levels</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Change from baseline in total GAG, DS GAG, and HS GAG (/creatinine ratio) measured in tissues including blood, liver and cerebrospinal fluid (CSF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAV2/6 clearance in plasma, saliva, urine, stool, and semen</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>AAV2/6 clearance by measuring vector genomes in plasma, saliva, urine, stool, and semen by PCR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>MPS I</condition>
  <arm_group>
    <arm_group_label>Cohort 1: SB-318: Starting Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-318</intervention_name>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
    <arm_group_label>Cohort 1: SB-318: Starting Dose</arm_group_label>
    <arm_group_label>Cohort 2: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_label>Cohort 3: SB-318 at Next Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 5 years of age&#xD;
&#xD;
          -  Clinical diagnosis of attenuated MPS I deficiency (Hurler-Scheie, Scheie, or Hurlers&#xD;
             status post-HSCT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known to be unresponsive to ERT&#xD;
&#xD;
          -  Neutralizing antibodies to AAV 2/6&#xD;
&#xD;
          -  Serious intercurrent illness or clinically significant organic disease (unless&#xD;
             secondary to MPS I)&#xD;
&#xD;
          -  Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or&#xD;
             hepatitis C or HIV 1/2&#xD;
&#xD;
          -  Lack of tolerance to laronidase treatment with significant IARs or occurrence of&#xD;
             anaphylaxis&#xD;
&#xD;
          -  Markers of hepatic dysfunction&#xD;
&#xD;
          -  Creatinine ≥ 1.5 mg/dL&#xD;
&#xD;
          -  Contraindication to the use of corticosteroids for immunosuppression&#xD;
&#xD;
          -  Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use&#xD;
             (topical treatment allowed)&#xD;
&#xD;
          -  Participation in prior investigational drug or medical device study within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Prior treatment with a gene therapy product&#xD;
&#xD;
          -  Elevated or abnormal circulating α-fetoprotein (AFP)&#xD;
&#xD;
          -  Weight &lt;20 kg at Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>MPS I</keyword>
  <keyword>Hurler-Scheie syndrome</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Gene Editing</keyword>
  <keyword>Zinc Finger</keyword>
  <keyword>SB-318</keyword>
  <keyword>Rare</keyword>
  <keyword>Genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>Genome editing</keyword>
  <keyword>Empowers</keyword>
  <keyword>ZFN</keyword>
  <keyword>Hurler</keyword>
  <keyword>Gene Specific Targeted Insertion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

